Company is among the few companies in the sector getting pulled up by FDA for violations at its factories in India.
JB Chemicals & Pharmaceuticals has entered into an in-licensing agreement with Ranbaxy Laboratories for marketing its herbal brand 'Doktor Mom' in Romania.
FDA allows Teva to launch Nexium generic; Cipla, which supplies formulation, to gain
US drug maker Merck & Co has terminated its nearly two-year-old alliance with Ranbaxy Laboratories to develop anti-infective medicines, which could have fetched the Indian firm $100 million over a period of five years.
Pharmaceuticals major Ranbaxy Laboratories plans to leverage the cost advantage of Chinese raw materials by making China its major active pharmaceutical ingredient sourcing hub.
Less than three months after roaring into us market with generic for cholesterol-reducing Lipitor, Dept of Justice files for permanent injunction against Ranbaxy.
The recalled drugs were manufactured and distributed in the US by Ohm Laboratories.
The Halol facility is important for the company as it accounts for 10 per cent of Sun Pharma's sales.
Sun Pharmaceutical said Ranbaxy shareholders will get 0.8 Sun Pharma shares for each Ranbaxy share.
Ukraine is currently in the middle of a strategic offensive into Russia's Kursk region.
Mylan had sued the United States Food and Drugs Administration for providing the exclusive right to Ranbaxy, alleging the permission was given on the basis of 'falsified data'.
The Gurgaon-headquartered drug maker, set to be acquired by another leading domestic company, Sun Pharmaceutical Industries, reported a consolidated net loss of Rs 186 crore for the quarter ended June.
The US arm of Ranbaxy pleaded guilty to seven felonies relating to the manufacture and distribution of certain adulterated drugs
Ranbaxy Laboratories Ltd said it has not received any notice from National Pharmaceutical Pricing Authority to deposit Rs 15 million as penalty for pricing flaws.
The group's testing lab chain SRL Ranbaxy has been renamed as Religare Super Laboratories. RanAir, its charter aviation company will be known as Religare Voyages. About 15 group companies, including joint ventures like Religare Macquarie Private Wealth, Religare Aegon and Vistaar Religare have come under the umbrella brand Religare.
Malvinder Singh, President (Pharmaceuticals) and Executive Director, Ranbaxy, says the company aims to touch $5 billion in revenues by 2012, with growth coming from American and European markets.
It had posted net profit of Rs 125.75 crore (Rs 1.25 billion) during the January-March quarter of the previous fiscal, 2012-13.
It has hired consultants to advise it on a strategic project and compliance issues in the US. It also needs to improve employee morale.
The products would be marketed and promoted jointly by Nippon Chemiphar and Nihon Pharmaceutical and sold in Japan under the Ranbaxy/Nihon Pharmaceutical Industry Ltd label.
Sun Pharma to retain these in most markets; US could be the exception, where the Ranbaxy name has taken a hit.
Under the terms of the deal Ranbaxy will drop litigation it initiated in November 2005 and will sell Nexium from May 2014 - the expiry date of the first of a series of patents. Under US law Ranbaxy would be the exclusive generic distributor for the first six months.
Sun gets RBI nod for transfer of Ranbaxy overseas investments.
Pharma major, Ranbaxy Laboratories Ltd has entered into a joint venture agreement with South African Community Investment Holdings to market and sell its range of Anti-Retroviral products in African markets.
Ranbaxy Laboratories has signed an agreement with Geneva's Medicines for Malaria Venture for developing synthetic peroxide anti-malarial drug
Ranbaxy's troubled plants in India could see a turnaround as Sun Pharma has experience in doing so.
Ranbaxy Laboratories Ltd on Friday raised its equity stake to 50 per cent in Nihon Pharmaceutical Industry.
Having cut eight deals last year, the $1.3 billion pharma major Ranbaxy probably has the sharpest negotiating skills in the business.
Ranbaxy Laboratories on Tuesday announced a business alliance with Orchid Chemicals and Pharmaceuticals across multiple geographies and therapies, for finished dosage formulations and bulk drugs. The new alliance will explore new products and markets without disturbing the existing alliances. The deal is independent of any commitment related to management control and is a pure arm's length, independent strategic biz alliance. Ranbaxy will benefit from Orchid's future products
Leading pharmaceutical company Ranbaxy Laboratories on Tuesday said its global sales had crossed the $1 billion mark in February 2003-February 2004 on a moving annual total (MAT) basis.
Leading Indian drug firm Ranbaxy has launched court battles in Britain and the US against the American pharmaceutical giant Pfizer for the rights to produce the cholesterol drug atorvastatin at a cheaper price.
Pharmaceutical company Ranbaxy Laboratories said on Monday its UK subsidiary has won a patent case over solvent-free clarithromycin and that it has launched the drug.
Ranbaxy Laboratories Ltd on Monday said Nihon Pharmaceuticals Industry Ltd, a JV between the company and Nippon Chemiphar Ltd, has launched its first co-developed product Vogseal 0.2mg and 0.3mg tablets in Japan.\n\n
Ranbaxy's investment in the six-year-old joint venture for the 50 per cent stake is estimated at Rs 30.5 crore (Rs 305 million). Industry sources said the deal was unlikely to impact Ranbaxy's financials as revenues and investment in the joint venture was not significant. Sources said revenues from NPI were only $25 million in 2007 through the sale of four generic products.
Leading pharmaceutical firms such as Cipla and Ranbaxy are among the firms pulled up by the drug price regulator National Pharmaceuticals Pricing Authority (NPPA) for overcharging.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances